论文部分内容阅读
目的:探讨血清癌抗原125(CA125)、骨桥蛋白(OPN)、人激肽释放酶6(h K6)和人激肽释放酶10(h K10)联合检测对卵巢上皮癌早期诊断的临床价值。方法:选取卵巢上皮癌患者44例、卵巢上皮类良性肿瘤患者50例及健康妇女50例的血清样品,分别用酶联免疫吸附法及微粒子化学发光法测定OPN、CA125、h K6和h K10含量。结果:卵巢上皮癌组血清OPN、CA125、h K6和h K10水平明显高于卵巢上皮类良性肿瘤组及对照组,组间比较,差异具有统计学意义(P<0.05);Ⅲ期和Ⅳ期卵巢上皮癌患者OPN、CA125、h K6和h K10水平明显高于I期和Ⅱ期患者,组间比较,差异具有统计学意义(P<0.05)。OPN、CA125、HK6和h K10检测的敏感度分别为59.1%、65.9%、56.8%、61.3%;联合检测的敏感度为95.45%。结论:血清OPN、CA125、h K6和h K10联合检测可提高卵巢上皮癌早期诊断的敏感性。
Objective: To investigate the clinical value of combined detection of serum tumor antigen 125 (CA125), osteopontin (OPN), human kallikrein 6 (h K6) and human kallikrein 10 (h K10) in the early diagnosis of ovarian epithelial carcinoma . Methods: Serum samples of 44 patients with epithelial ovarian cancer, 50 patients with benign ovarian tumors and 50 healthy women were selected for serum samples. The contents of OPN, CA125, h K6 and h K10 were determined by enzyme-linked immunosorbent assay and microparticle chemiluminescence . Results: The levels of serum OPN, CA125, h K6 and h K10 in ovarian epithelial cancer group were significantly higher than those in benign ovarian epithelial tumor group and control group, the difference was statistically significant (P <0.05); Ⅲ and Ⅳ The levels of OPN, CA125, h K6 and h K10 in patients with epithelial ovarian cancer were significantly higher than those in patients with stage I and II. The difference was statistically significant (P <0.05). The sensitivities of OPN, CA125, HK6 and h K10 were 59.1%, 65.9%, 56.8% and 61.3%, respectively. The sensitivity of combined detection was 95.45%. Conclusion: The combined detection of serum OPN, CA125, h K6 and h K10 can improve the sensitivity of early diagnosis of epithelial ovarian cancer.